AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: molecule

newssourceFORcompanyinformationcontent1marketreleases

Generative AI Services Market to Hit USD 43.8 Billion by 2030, Fueled by SaaS & Healthcare Demand | Valuates Reports

Generative AI Services Market is Segmented by Type (IaaS, PaaS, SaaS), by Application (Marketing and Advertising, Technology, Consulting, Teaching, Accounting, Healthcare). BANGALORE, India, June 24,...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to...

For media and investors only

Varda Space Industries Launches W-4 with the FAA’s First-Ever Reentry Vehicle Operator License and Debuts an In-House Satellite Bus

The company's fourth mission will focus on demonstrating its new satellite bus, an in-house heatshield, and solution-based pharmaceutical processing. EL SEGUNDO, Calif., June 23,...

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine’s DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMolecule

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers